Pharming

Pharming visits Beursplein 5

Sijmen de Vries, CEO of the Euronext listed Pharming (ticker symbol: PHARM) sounds the gong at the Amsterdam exchange. Pharming Group has been making considerable progress over the recent months. The company is now to become the first and only Dutch biotech company to get to commercialise a self- developed product, RUCONEST®, in North America.

This therapy is approved for acute attacks of Hereditary Angio-Edema (HAE), instant and sometimes life threatening swellings in various body parts including the hands, feet, face and airway. This as result of the closing of an agreement with its US partner Valeant Pharmaceuticals to buy back the marketing rights of its own medicine in the US, Canada and Mexico. In addition, following an amendment of its agreement with its EU partner Sobi, Pharming also takes on commercialization of RUCONEST in most of Western- Europe. Pharming recently also reported positive results from a Phase II trial for the prevention of HAE with RUCONEST.

Based on closing the US deal with Valeant, Pharming is also the first Dutch biotech company that is about to turn profitable. Pharming has transformed itself into a real pharmaceutical company, developing and bringing its own innovative products for the safe and effective treatment of rare diseases and unmet medical needs.

For more information: www.pharming.com

Download photo